John Dyer
Managing Director Aquilo
John Dyer, Managing Director, is based in Aquilo Partner’s Boston office. He brings extensive experience in healthcare investment banking, spanning partnerships, sell-side advisory, acquisitions, divestitures, IPOs, and follow-on offerings across the biotechnology, specialty pharma, and diagnostics sectors.
Prior to Aquilo Partners in 2009, John was an Executive Director at JPMorgan, where he advised biotechnology clients on a broad range of strategic and financing engagements. Before joining JPMorgan in 2006, John spent six years with Cowen and Company, focusing on small and mid-cap biotechnology clients in New York and San Francisco.
John received a Master’s degree in International Business Administration from the Moore School of Business at the University of South Carolina, where he graduated Beta Gamma Sigma, and a BA degree from the University of Virginia.
Seminars
- Which pain targets, technologies and therapeutic approaches are attracting the greatest investment interest today?
- What data package is required to move a program from scientific promise to an investable opportunity?
- How are investors assessing technical, clinical and commercial risk in an increasingly competitive pain landscape?
- Where do investors see the biggest opportunities and unmet needs shaping the next wave of pain innovation?
- Assess how recent transactions, including Lilly’s acquisitions of SiteOne Therapeutics and 4E Therapeutics, and AbbVie’s licensing agreement with Haisco Pharmaceutical for HSK21542, are reshaping partnering and investment priorities across pain
- Define the translational, clinical and commercial evidence packages required to progress from early interest to competitive deal activity
- Explore which mechanisms, indications and patient populations are attracting the strongest external interest, from NaV1.8 inhibitors and peripheral targets through to neuroimmune and disease-modifying approaches
- Identify what differentiates a partnerable pain asset today, including target validation, patient selection strategy, clinical positioning and commercial potential
